ADMA Biologics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2022

Intangible assets at September 30, 2022 and December 31, 2021 consist of the following:

	September 30, 2022						December 31, 2021
			Accumulated						Accumulated
	Cost		Amortization		Net		Cost		Amortization		Net
Trademark and other intangible rights related to Nabi-HB	$	4,100,046	$	3,123,845	$	976,201	$	4,100,046	$	2,684,554	$	1,415,492
Rights to intermediates		907,421		691,368		216,053		907,421		594,145		313,276
	$	5,007,467	$	3,815,213	$	1,192,254	$	5,007,467	$	3,278,699	$	1,728,768

Intangible Asset Future Aggregate Amortization Expense

All of the Company’s intangible assets were acquired in the Biotest Transaction. Amortization expense related to these intangible assets was $0.5 million for the nine months ended September 30, 2022 and 2021 and $0.2 million for the three months ended September 30, 2022 and 2021. Estimated future aggregate amortization expense is expected to be as follows:

Remainder of 2022	$	178,838
2023		715,352
2024		298,064